United Therapeutics Competitive Intelligence & Landscape

United Therapeutics Corporation (Nasdaq: UTHR) is a biotechnology company founded in 1996 with a mission to develop treatments for rare, deadly diseases [ir.unither.com]. The company was established by a family seeking a cure for their daughter's pulmonary arterial hypertension (PAH) [ir.unither.com].

United Therapeutics operates with a bold and unconventional approach, focusing on transforming the treatment of rare diseases and expanding the availability of transplantable organs [unither.com/home]. They are inspired by stakeholders to generate strong shareholder returns, provide effective therapeutics, and respect employees, communities, and the environment [unither.com/home].

United Therapeutics specializes in cardiopulmonary disease and organ transplantation, leveraging cutting-edge science and a patient-centric focus [pipeline.unither.com]. Their core products include six FDA-approved therapies for PAH, pulmonary hypertension associated with interstitial lung disease (PH-ILD), and neuroblastoma, a rare pediatric cancer [ir.unither.com]. Beyond pharmaceuticals, the company is also involved in organ manufacturing programs, utilizing advanced technology and engineering to increase the supply of transplantable organs [pipeline.unither.com]. Their Silver Spring co-headquarters in Maryland, located at 1000 Spring Street, houses office, laboratory, and manufacturing spaces where they produce treatments like treprostinil and Unituxin®, and conduct ex-vivo lung perfusion procedures [unither.com/about-us/locations-and-subsidiaries].

The target market for United Therapeutics includes patients suffering from rare and life-threatening conditions, particularly those with cardiopulmonary diseases and individuals in need of organ transplants [pipeline.unither.com]. The company's headquarters are co-located in Silver Spring, MD and Research Triangle Park, NC [unither.com/about-us/locations-and-subsidiaries].

United Therapeutics became a public benefit corporation, aligning its corporate structure with its foundational goals of developing novel pharmaceutical therapies and finding a cure for end-stage organ diseases [unither.com/about-us/public-benefit-corporation].

United Therapeutics (unither.com) is a biotechnology company dedicated to developing treatments for rare and life-threatening conditions, with a primary focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension-associated with interstitial lung disease (PH-ILD) [https://www.unither.com/research-and-medicine/therapeutic-areas]. The company's product portfolio addresses critical and unmet needs in these areas, including six FDA-approved therapies for PAH, PH-ILD, and neuroblastoma [https://ir.unither.com/]. While specific current pricing plans and tiers are not publicly detailed in the provided sources, United Therapeutics emphasizes a patient-centric approach to market access and pricing, considering benefits to patients, society, and the healthcare system [https://corporateresponsibility.unither.com/~/media/Files/U/Unither-Corp/reports-and-resources/ut-patient-centricity-overview.pdf].

Pricing for United Therapeutics products, such as Orenitram® (treprostinil) Extended Release, is often based on Average Wholesale Prices (AWP). These AWPs are established and made publicly available by a third-party publisher [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/information-for-vermont-prescribers-of-prescription-drug.pdf]. It's important to note that the price paid by consumers may differ from the listed AWP, and these prices do not necessarily reflect the cost per course of treatment [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/corporate-governance/Long-Form-UT-11_2_23.pdf]. The company also acknowledges the complexity of pricing and rebate calculations, which can vary significantly among products and programs and are subject to interpretation [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/uthr-10q-q1-2026.pdf].

United Therapeutics offers patient support programs like United Therapeutics Cares, which provides ongoing, one-on-one education and support throughout a patient's treatment journey [https://www.unither.com/patients/support-programs]. This indicates a commitment to assisting patients beyond just providing the medication. There is no information available in the provided sources about free versus paid features or recent pricing changes specifically, but the general approach highlights consideration for access and affordability within the context of rare disease treatments.

United Therapeutics (unither.com) actively seeks to expand its workforce with individuals who embody a sense of urgency and curiosity, aiming to innovate and challenge the status quo [unither.com/careers/to-be-a-unitherian]. The company emphasizes its commitment to being an Equal Opportunity Employer, treating all applicants and employees without regard to protected veteran status, race, religion, national origin, gender, or age [unither.com/careers/equal-opportunity-employer]. This approach signals a strategic focus on diverse talent acquisition to support its mission of transforming the treatment of rare diseases and expanding the availability of transplantable organs [unither.com/home].

United Therapeutics maintains a robust and transparent hiring process, posting all legitimate job openings exclusively on its official careers page at unither.com/careers [unither.com/careers/recruitment-fraud-warning]. This measure helps protect potential candidates from recruitment fraud, indicating a company culture that values security and integrity in its hiring practices. The availability of detailed information on benefits, amenities, and awards further suggests a competitive and employee-centric recruitment strategy designed to attract and retain top talent [unither.com/careers/benefits-and-amenities][unither.com/careers/awards-and-recognitions].

The company’s strategic hiring patterns align with its bold and unconventional vision, reflecting a dedication to scientific advancement and patient care [unither.com/home][unither.com/medical-professionals/science-medical-affairs/about-science-and-medical-affairs]. While specific recent hiring trends or layoffs are not detailed in the provided sources, the emphasis on attracting individuals who can "act with a sense of urgency and curiosity to innovate" [unither.com/careers/to-be-a-unitherian] suggests a continuous drive for growth and development within its therapeutic areas. The focus on medical affairs, collaboration with the scientific community, and research [unither.com/medical-professionals/science-medical-affairs/about-science-and-medical-affairs] implies ongoing recruitment for roles supporting these critical functions.

United Therapeutics (unither.com) has demonstrated robust financial performance, achieving record revenues in recent years. For the full year 2024, United Therapeutics reported total revenues of $2.88 billion, reflecting a 24% increase over 2023 [ir.unither.com/press-releases/2025/02-26-2025-113025174]. This growth continued into 2025, with revenues rising to a record $3.18 billion, an 11% increase from 2024 [ir.unither.com/press-releases/2026/02-25-2026-113016583]. The company's products, including Tyvaso DPI and nebulized Tyvaso, Adcirca, Remodulin, and Unituxin, are significant contributors to these revenues [ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/uthr-10-k-2025.pdf].

Key product sales have been strong, with combined net product sales for Tyvaso DPI and nebulized Tyvaso reaching $1,620.4 million in 2024, representing 56% of total revenues [ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/uthr-4q24-10k.pdf]. The company also reported record financial results for the third quarter of 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso and Orenitram [ir.unither.com/press-releases/2025/10-29-2025-103021766].

In terms of financial health indicators, United Therapeutics maintains substantial current assets. As of March 31, 2026, total current assets were $2,872.0 million, including $1,279.7 million in cash and cash equivalents and $874.0 million in marketable investments [ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/uthr-10q-q1-2026.pdf]. For September 30, 2025, current assets stood at $3,494.0 million, with $1,340.1 million in cash and cash equivalents and $1,427.5 million in marketable investments [ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2025/uthr-10q-q3-2025.pdf]. These figures highlight United Therapeutics' strong liquidity and financial position, supporting its ongoing operations and potential future strategic initiatives.

United Therapeutics (unither.com) actively participates in various industry and investor events, showcasing its commitment to innovation and transparency in the healthcare sector. The company's executives frequently present overviews and updates at major financial and healthcare conferences. For instance, in 2026, United Therapeutics had presentations scheduled at the Jefferies Global Healthcare Conference, the RBC Capital Markets Global Healthcare Conference, and its own First Quarter 2026 event [https://ir.unither.com/events-and-presentations].

Beyond investor-focused gatherings, United Therapeutics also makes significant contributions to scientific conferences by presenting new data from its commercial and development portfolios. The company announced 12 new data presentations at the American Thoracic Society (ATS) International Conference from May 15-20, 2026, in Orlando [https://ir.unither.com/press-releases/2026/05-11-2026-113018650]. Similarly, 11 new data presentations were shared at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions in April 2026 in Toronto, Canada [https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2026/04-20-2026-ishlt-2026-press-release-for-distribution.pdf].

United Therapeutics' engagement extends to prestigious events like the 44th Annual J.P. Morgan Healthcare Conference, where Dr. Martine Rothblatt, Chairperson and CEO, presented a company overview and update in January 2026 [https://ir.unither.com/press-releases/2026/01-05-2026-120012250]. Other notable participations include the TD Cowen 46th Annual Health Care Conference [https://ir.unither.com/press-releases/2026/02-23-2026-120020568] and the Leerink Global Healthcare Conference [https://ir.unither.com/press-releases/2026/03-03-2026-120017829], demonstrating a consistent presence at key industry forums. In 2025, the company also presented research at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands [https://ir.unither.com/press-releases/2025/09-12-2025-120014135].

These event participations underscore United Therapeutics' dedication to sharing advancements, engaging with the investment community, and contributing to the broader scientific dialogue in the fields pertinent to its therapeutic areas.